ClinicalTrials.gg
CompletedNCT02194244Updated Nov 2, 2016

Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662

A Phase 1 interventional study of RG1662 granules and RG1662 tablet in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will compare the pharmacokinetic performance of film-coated tablet and granule formulations of RG1662 under fed and fasted conditions in healthy volunteers. A randomized, four-period, four-treatment crossover design is used. In each period, each volunteer will receive a single oral dose of the tablet or granule formulation either with or without food.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female volunteers, 18 to 60 years of age, inclusive

Exclusion criteria

Exclusion Criteria:

  • A history of epilepsy, convulsions or significant head injury
  • Any other abnormalities, concomitant diseases or ongoing medical conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Granules Fasted

    Drug: RG1662 granules

  • Experimental
    Granules Fed

    Drug: RG1662 granules

  • Active comparator
    Tablet Fasted

    Drug: RG1662 tablet

  • Active comparator
    Tablet Fed

    Drug: RG1662 tablet

Interventions

  • Single dose, oral administration of RG1662 immediate release granules

  • Single dose, oral administration of film-coated RG1662 immediate release tablet

06

What researchers measure

Primary outcomes

  1. Granules Fed (test): RG1662 plasma exposure, area under the concentration-time curve

    Time frame: Up to 9 weeks

  2. Granules Fasted (test): RG1662 plasma exposure, area under the concentration-time curve

    Time frame: Up to 9 weeks

  3. Tablet Fed (reference): RG1662 plasma exposure, area under the concentration-time curve

    Time frame: Up to 9 weeks

  4. Tablet Fasted (reference): RG1662 plasma exposure, area under the concentration-time curve

    Time frame: Up to 9 weeks

Secondary outcomes

  1. Tablet formulation: RG1662 plasma exposure ratio between fed (test) and fasted (reference) conditions, estimated from area under the concentration-time curve measurements

    Time frame: Up to 9 weeks

  2. Granule formulation: RG1662 plasma exposure ratio between fed (test) and fasted (reference) conditions, estimated from area under the concentration-time curve measurements

    Time frame: Up to 9 weeks

  3. Palatability of the granule formulation, as assessed by questionnaire

    Time frame: Day 1, Day 3 in granule administration periods

  4. Safety: Incidence of adverse events with either formulation

    Time frame: Up to 9 weeks

07

Study locations

1 site
  • Leeds, LS2 9LH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2014
First posted
Jul 18, 2014
Start
Aug 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02194244
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2014
Start date
Aug 2014
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion